Vallerie V. McLaughlin, MD, FACC
Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine
University of Michigan Hospital

Printed as of 11/5/2026

Disclosures

Personal Commercial (10)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
caremark	Consultant Fees/Honoraria	Modest (< $5,000)	*Pulmonary Hypertension and Venous Thromboembolic*
Gossamer Bio	Research/Research Grants	Significant (>= $5,000)	
Gossamer Bio	Consultant Fees/Honoraria	Modest (< $5,000)	*Pulmonary Hypertension and Venous Thromboembolic*
Janssen Pharmaceuticals, Inc	Research/Research Grants	Significant (>= $5,000)	
Janssen Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= $5,000)	
Liquidia	Research/Research Grants ‡ *ASCENT*	Significant (>= $5,000)	*Pulmonary Hypertension and Venous Thromboembolic*
Liquidia	Consultant Fees/Honoraria	Significant (>= $5,000)	*Pulmonary Hypertension and Venous Thromboembolic*
Merck & Co., Inc.	Research/Research Grants	Significant (>= $5,000)	*Pulmonary Hypertension and Venous Thromboembolic*
Merck & Co., Inc.	Consultant Fees/Honoraria	Significant (>= $5,000)	*Pulmonary Hypertension and Venous Thromboembolic*
United Therpeutics	Consultant Fees/Honoraria	Significant (>= $5,000)	*Pulmonary Hypertension and Venous Thromboembolic*

Additional Personal Commercial Disclosures for Education Activities (3)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Inhibikase	Consultant Fees/Honoraria	Significant (>= $5,000)	*Pulmonary Hypertension and Venous Thromboembolic*
Pulmovant/Roivant	Consultant Fees/Honoraria	Significant (>= $5,000)	*Pulmonary Hypertension and Venous Thromboembolic*
regeneron	Consultant Fees/Honoraria	Modest (< $5,000)	*Pulmonary Hypertension and Venous Thromboembolic*

Personal Organizational or Other Non-Commercial (1)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
AllRock	Consultant Fees/Honoraria	Significant (>= $5,000)	*Pulmonary Hypertension and Venous Thromboembolic*

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 8/2/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 8/2/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 8/2/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 8/2/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.